Expand Treatment Options for Your Patients with Global Access Intelligence
Secure physician-to-physician portal for peer case review, clinical trial matching, and access to 200+ partner institutions across 8 countries. Evidence-based. HIPAA-aligned. Free for referring physicians.
A Candid Note for Referring Oncologists
Myth: "Medical tourism platforms are simply brokerages that push patients to the highest-paying hospital."
Reality: We explicitly decline cases that lack clinical rationale, recommend local standard of care when it's the better option, and publish our institutional revenue sources on our Financial Transparency page. Our peer reviewers include independent oncologists who are not affiliated with the receiving institution. You retain full clinical authority — we provide access intelligence, not medical decisions. If your patient does not need to travel, we will say so in writing.
What the Physician Portal Offers
Comprehensive tools to expand treatment options for your patients with advanced cancer.
Peer Case Review
Submit de-identified patient records for evidence-based second opinions from specialist oncologists in our network.
- De-identified case submission
- Review by 2-3 specialist oncologists
- Evidence-based treatment recommendations
- Clinical trial eligibility assessment
- Response within 48-72 hours
Clinical Trial Matching
Access our database of 700+ active trials. Match your patients to appropriate studies in real-time.
- 700+ CAR-T trials in China
- Trials in 7 additional countries
- Eligibility criteria matching
- Real-time availability updates
- Enrollment coordination support
Institution Access
Direct connections to 200+ partner institutions including public hospitals, private centers, and trial sites.
- 8 countries: China, India, S. Korea, Turkey, USA, Germany, Singapore
- JCI-accredited institutions
- Public and private hospitals
- Clinical trial sites
- Direct physician-to-physician communication
Outcome Data
Access anonymized outcome data from our network to inform your clinical decisions.
- Response rates by cancer type
- Adverse event profiles
- Cost transparency data
- Published clinical evidence
- Comparative effectiveness data
Patient Referral
Securely refer patients for treatment coordination. We handle logistics, you retain clinical oversight.
- Secure patient referral form
- Transparent cost estimates
- Travel and visa coordination
- Multi-language support
- Ongoing case updates
Educational Resources
Stay updated on the latest advances in cellular therapy and immunotherapy.
- Webinars with key opinion leaders
- Clinical trial updates
- Treatment guideline summaries
- Case studies and presentations
- PubMed-indexed research
How the Referral Process Works
A clear, transparent 5-step process from referral to treatment completion.
Submit Case
Submit de-identified patient records through our secure HIPAA-aligned portal.
Peer Review
Our network of specialist oncologists provides evidence-based recommendations within 48-72 hours.
Trial Matching
If eligible, we match the patient to appropriate clinical trials or treatment programs.
Coordination
We coordinate travel, visa, accommodation, and logistics. You retain clinical oversight.
Ongoing Updates
Receive regular updates on treatment progress. Direct physician-to-physician communication available.
Clinical Trial Landscape
Access to the world's most active clinical trial ecosystem for advanced cancer therapies.
🇨🇳 China
🇰🇷 South Korea
🇸🇬 Singapore
🇮🇳 India
🇹🇷 Turkey
🇺🇸 USA & 🇩🇪 Germany
Access Intelligence: Clinical Need → Capability → Path
An evidence-informed framework to match patient clinical needs with required capabilities and potential access pathways.
| Clinical Need | Required Capability | Potential Access Paths |
|---|---|---|
| Advanced hematologic malignancy after multiple lines | Certified CAR-T center + apheresis + ICU-level CRS/ICANS management | Regulated markets with approved CAR-T products; academic centers with documented trial portfolios |
| Rare or refractory presentation | Early-phase trial access + molecular tumor board | Centers with active investigator-initiated studies and rapid screening workflows |
| Solid tumor requiring multidisciplinary coordination | MDT + advanced imaging + surgical/radiation/medical oncology integration | High-volume academic centers with documented multidisciplinary outcomes |
Security & Compliance
Patient data is protected with enterprise-grade security and HIPAA-aligned protocols.
HIPAA-Aligned Security
End-to-end encryption, secure document upload, access controls, and audit trails. We do not store protected health information (PHI) longer than necessary.
De-identified Data
All case submissions use de-identified patient data. No personally identifiable information (PII) is shared without explicit consent.
Encrypted Transmission
256-bit SSL encryption for all data transmission. Secure file upload with virus scanning and integrity verification.
Access Controls
Role-based access control ensures only authorized personnel can view case information. Multi-factor authentication required.
Compliance Documentation
Business Associate Agreements (BAA) available. GDPR-compliant for European patients. Regular security audits conducted.
Audit Trails
Complete audit logs of all data access and modifications. Transparent record-keeping for compliance and quality assurance.
Frequently Asked Questions
Common questions from physicians about our referral portal and services.
What is the Physician Referral Portal?
A secure, HIPAA-aligned platform for licensed oncologists to refer patients for peer case review, clinical trial matching, and access to advanced therapies at 200+ partner institutions across 8 countries. The service is free for referring physicians.
How does peer case review work?
Submit de-identified patient records through our secure portal. Our network of specialist oncologists provides evidence-based second opinions within 48-72 hours, including treatment recommendations and clinical trial eligibility assessment.
What clinical trials are available?
Access to 700+ active CAR-T clinical trials in China alone, plus trials in South Korea, Singapore, India, Turkey, Germany, and USA. Trials cover hematologic malignancies (ALL, AML, CLL, DLBCL, myeloma) and solid tumors (GBM, melanoma, lung, liver, pancreatic).
Is there a cost for physicians?
No. The physician referral portal and all coordination services are completely free for licensed oncologists. Our platform is sustained through institutional partnerships with hospitals, not physician fees.
How is patient data protected?
Our platform uses HIPAA-aligned security protocols including end-to-end encryption, de-identification of patient data, secure document upload, and access controls. We do not store protected health information (PHI) longer than necessary for case review.
What is CancerCareE's role?
CancerCareE is an access coordination platform, not a healthcare provider. We do not diagnose, treat, or make medical decisions. We facilitate connections between physicians, patients, and partner institutions. All medical decisions remain with the treating physician.
Can I communicate directly with the treating physician abroad?
Yes. We facilitate direct physician-to-physician communication between you and the treating oncologist at the partner institution. You retain clinical oversight throughout the treatment process.
What happens after treatment is completed?
We coordinate follow-up care planning and provide treatment summaries. Long-term follow-up can be managed locally with remote support from the treating institution as needed. We facilitate continuity of care.
Continue Your Clinical Research
Independent Advisors
Specialist oncologists reviewing international cases daily.
Meet the Team →Legal Framework
Our role, liability boundaries, and physician protections.
Read Legal Framework →Financial Transparency
How we are funded — $0 physician fees, institutional model.
Financial Disclosure →For Institutions
Partnership framework for hospitals and health systems.
Partnership Guide →Ready to Expand Your Patients' Options?
Submit a de-identified case for free peer review. Our specialist oncologists respond within 48–72 hours with evidence-based recommendations.